Roxane Rohani

Roxane Rohani

Auto-generated profile, based on publicly available information

Roxane Rohani

Discipline of Cellular and Molecular Pharmacology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
NRNathaniel Rhodes
Nathaniel Rhodes
RRRoxane Rohani
Roxane Rohani
PYPaul R. Yarnold
Paul R. Yarnold
APAnna E. Pawlowski
Anna E. Pawlowski
MMMichael Malczynski
Michael Malczynski
RWRichard G. Wunderink
Richard G. Wunderink
Methicillin-resistant Staphylococcus aureus (MRSA) is an uncommon but serious cause of community-acquired pneumonia (CAP). A lack of validated MRSA CAP risk factors can result in overuse of empirical broad-spectrum antibiotics.

18 March 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SASean Avedissian
Sean Avedissian
RRRoxane Rohani
Roxane Rohani
JBJohn Bradley
John Bradley
JLJennifer Le
Jennifer Le
NRNathaniel Rhodes
Nathaniel Rhodes
Augmented renal clearance (ARC) can occur in critically ill pediatric patients receiving aminoglycosides such as gentamicin and tobramycin, yet optimal dosing strategies for ARC are undefined. We evaluated the probability of achieving efficacious or toxic exposures in pediatrics. Parallel population modeling of concentration strategies were pursued using Pmetrics v1.5.2 (nonparametric) and Monolix v2019R2 (parametric).

14 December 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
RRRoxane Rohani
Roxane Rohani
PYPaul R. Yarnold
Paul R. Yarnold
MSMarc Scheetz
Marc Scheetz
MNMichael Neely
Michael Neely
MKMengjia Kang
Mengjia Kang
NRNathaniel Rhodes
Nathaniel Rhodes
It is unclear whether plasma is a reliable surrogate for target attainment in the epithelial lining fluid (ELF). The objective of this study was to characterize meropenem target attainment in plasma and ELF using prospective samples. The first 24-hour T >MIC was evaluated vs 1xMIC and 4xMIC targets at the patient (i.e., fixed MIC of 2 mg/L) and population [i.e., cumulative fraction of response (CFR) according to EUCAST MIC distributions] levels for both plasma and ELF. Among 65 patients receiving ≥24 hours of treatment, 40% of patients failed to achieve >50% T >4xMIC in plasma and ELF, and 30% of patients who achieved >50% T >4xMIC in plasma had 95% T >MIC in plasma had 115 mL/min were less likely to achieve >50%T >4xMIC in ELF ( P < 0.025). In the population, CFR for Escherichia coli at 1xMIC and 4xMIC was >97%. For Pseudomonas aeruginosa , CFR was ≥90% in plasma and ranged 80%–85% in ELF at 1xMIC when a loading dose was applied. CFR was reduced in plasma (range: 75%–81%) and ELF (range: 44%–60%) in the absence of a loading dose at 1xMIC. At 4xMIC, CFR for P. aeruginosa was 60%–86% with a loading dose and 18%–62% without a loading dose. We found that plasma overestimated ELF target attainment inup to 30% of meropenem-treated patients, CRCL >115 mL/min decreased target attainment in ELF, and loading doses increased CFR in the population.

23 July 2022 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
RRRoxane Rohani
Roxane Rohani
MSMarc Scheetz
Marc Scheetz
HDHelen K Donnelly
Helen K Donnelly
ADAlvaro Donayre
Alvaro Donayre
MKMengjia Kang
Mengjia Kang
NRNathaniel Rhodes
Nathaniel Rhodes
Critical illness reduces β-lactam pharmacokinetic/pharmacodynamic (PK/PD) attainment. We sought to quantify PK/PD attainment in patients with hospital-acquired pneumonia. Meropenem plasma PK data (n = 70 patients) were modelled, PK/PD attainment rates were calculated for empirical and definitive targets, and between-patient variability was quantified [as a coefficient of variation (CV%)]. Attainment of 100% T>4×MIC was variable for both empirical (CV% = 92) and directed (CV% = 33%) treatment. Individualization is required to achieve suggested PK/PD targets in critically ill patients.

2 November 2023 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
RRRoxane Rohani
Roxane Rohani
JMJacob Malakismail
Jacob Malakismail
ENEmmanuel Njoku
Emmanuel Njoku

8 January 2026 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
RPRadhika S. Polisetty
Radhika S. Polisetty
Spencer DurhamSpencer Durham
Spencer Durham
RRRoxane Rohani
Roxane Rohani
ACAshley Cluck
Ashley Cluck
ESElizabeth Sherman
Elizabeth Sherman
KSKristy Shaeer
Kristy Shaeer